A case of Stevens-Johnson syndrome treated with oral cyclosporine

Victoria Griffith; Amanda Ramnot; Sydney R Resnik; Barry I Resnik

doi:10.4103/jfmpc.jfmpc_1162_23

A case of Stevens-Johnson syndrome treated with oral cyclosporine

J Family Med Prim Care. 2023 Dec;12(12):3425-3428. doi: 10.4103/jfmpc.jfmpc_1162_23. Epub 2023 Dec 21.

Authors

Victoria Griffith¹, Amanda Ramnot², Sydney R Resnik³, Barry I Resnik^{3

4}

Affiliations

¹ Department of Graduate Medical Education, Memorial Healthcare, Pembroke Pines, FL, United States.
² Department of Internal Medicine, University of Miami/Jackson Health Systems, Miami, FL, United States.
³ Dr. Philip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL, United States.
⁴ Department of Dermatology, Resnik Skin Institute, Aventura, FL, United States.

Abstract

Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) can occur at any age and are commonly caused by adverse drug events. Rapid diagnosis of SJS/TEN is imperative, followed by immediate cessation of offending agent and induction of appropriate treatment. Cyclosporine, a calcineurin inhibitor, has been reported to have a promising therapeutic effect in SJS/TEN patients with few side effects. Diagnosis of SJS/TEN in children is especially challenging as many of the symptoms mimic that of an upper respiratory infection, or other viral entities such as cocksackie A, roseola, or herpes simplex virus. We recommend initiating cyclosporine modified treatment, especially in children, upon any suspicion of SJS/TEN in a patient in order to halt the disease progression as early as possible.

Keywords: Cyclosporine modified; Stevens-Johnson syndrome; toxic epidermal necrolysis.

Publication types

Case Reports